Ensysce Biosciences, Inc.
$0.48
▲
11.44%
2026-04-21 06:39:00
www.ensysce.com
NCM: ENSC
Explore Ensysce Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$4.49 M
Current Price
$0.48
52W High / Low
$4.85 / $0.31
Stock P/E
—
Book Value
$0.7
Dividend Yield
—
ROCE
-355%
ROE
-3.25%
Face Value
—
EPS
$-3.98
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
8
Beta
1.14
Debt / Equity
10.63
Current Ratio
1.59
Quick Ratio
1.59
Forward P/E
-0.21
Price / Sales
0.85
Enterprise Value
$-0.02 M
EV / EBITDA
0
EV / Revenue
-0.01
Rating
Strong Buy
Target Price
$16.45
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Inhibikase Therapeutics, Inc. | $1.81 | — | $238.98 M | — | -30.85% | -36.04% | $2.37 / $1.33 | $1.02 |
| 2. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 3. | Jazz Pharmaceuticals plc | $200.82 | — | $12.38 B | — | 5.5% | -8.47% | $207.48 / $97.5 | $70.3 |
| 4. | Jasper Therapeutics, Inc. | $1.06 | — | $28.56 M | — | -371.51% | -2.3% | $7.19 / $0.62 | $0.15 |
| 5. | Halozyme Therapeutics, Inc. | $68.8 | 26.89 | $8.18 B | — | 34.18% | 1.54% | $82.22 / $47.5 | $0.41 |
| 6. | OSR Holdings, Inc. | $0.6 | — | $19.87 M | — | 79.82% | -20.03% | $1.79 / $0.38 | $3.46 |
| 7. | Kymera Therapeutics, Inc. | $88.84 | — | $7.31 B | — | -20.82% | -25.78% | $103 / $24.43 | $19.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -2.78 M | -3.74 M | -1.75 M | -1.97 M | -3.58 M |
| Net Profit | -2.77 M | -3.73 M | -1.73 M | -1.95 M | -3.56 M |
| EPS in Rs | -0.3 | -0.4 | -0.19 | -0.21 | -0.38 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -10.24 M | -6.73 M | -10.72 M | -24.22 M |
| Net Profit | -10.18 M | -7.99 M | -10.61 M | -24.17 M |
| EPS in Rs | -1.1 | -0.86 | -1.14 | -2.61 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.45 M | 5.6 M | 2.71 M | 5.89 M |
| Total Liabilities | 4.57 M | 2.22 M | 3.36 M | 9.91 M |
| Equity | 3.21 M | 3.71 M | -0.32 M | -3.71 M |
| Current Assets | 7.24 M | 5.34 M | 2.29 M | 5.3 M |
| Current Liabilities | 4.57 M | 2.21 M | 3.33 M | 9.46 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.81 M | -7.5 M | -10.78 M | -17.89 M |
| Investing CF | -0.12 M | 0 M | 0 M | 0 M |
| Financing CF | 8.74 M | 9.88 M | 8.76 M | 8.77 M |
| Free CF | -7.93 M | -7.5 M | -10.78 M | -17.89 M |
| Capex | -0.12 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 24.74% | 56.09% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-12-06 | 1:0.0666667 |
| 2023-03-31 | 1:0.0833333 |
| 2022-10-28 | 1:0.05 |